These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36583283)

  • 1. Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes.
    Packer M
    Diabetes Obes Metab; 2023 May; 25(5):1143-1146. PubMed ID: 36583283
    [No Abstract]   [Full Text] [Related]  

  • 2. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
    Peacock SC; Lovshin JA; Cherney DZI
    Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
    [No Abstract]   [Full Text] [Related]  

  • 3. Sodium-glucose co-transporter 2 inhibition: the saga continues.
    Crea F
    Eur Heart J; 2022 Nov; 43(41):4215-4218. PubMed ID: 36316017
    [No Abstract]   [Full Text] [Related]  

  • 4. SGLT2 Inhibitors in Type 2 Diabetes Mellitus.
    Ferrannini G; Savarese G; Cosentino F
    Heart Fail Clin; 2022 Oct; 18(4):551-559. PubMed ID: 36216485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors: not every drug has the same effect.
    Staruschenko A
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1039-F1040. PubMed ID: 38695073
    [No Abstract]   [Full Text] [Related]  

  • 6. Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?
    Packer M
    Am J Med; 2018 May; 131(5):461-463. PubMed ID: 29309741
    [No Abstract]   [Full Text] [Related]  

  • 7. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
    Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growing clinical effect of SGLT2 inhibitors.
    Del Prato S
    Lancet Diabetes Endocrinol; 2023 Apr; 11(4):218-219. PubMed ID: 36878241
    [No Abstract]   [Full Text] [Related]  

  • 11. Dual SGLT1 and SGLT2 inhibition: more than the sum of its parts.
    Sánchez-Muñoz E; Requena-Ibáñez JA; Badimón JJ
    Rev Esp Cardiol (Engl Ed); 2024 Jul; 77(7):510-514. PubMed ID: 38521442
    [No Abstract]   [Full Text] [Related]  

  • 12. More CREDENCE for SGLT2 Inhibition.
    Verma S; Bhatt DL
    Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
    [No Abstract]   [Full Text] [Related]  

  • 13. The rise of SGLT2 inhibitors: the time is now for cardiovascular specialists to lead the charge.
    Norgard NB; Lopez-Candales A
    Postgrad Med; 2022 Jan; 134(1):11-13. PubMed ID: 34734540
    [No Abstract]   [Full Text] [Related]  

  • 14. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
    Kyriakos G; Quiles-Sanchez LV; Garmpi A; Farmaki P; Kyre K; Savvanis S; Antoniou VK; Memi E
    Curr Cardiol Rev; 2020; 16(4):258-265. PubMed ID: 31362691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial for the
    Lymperopoulos A
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors.
    Gunasekaran D; Shirali AC
    Kidney360; 2023 Sep; 4(9):e1322-e1324. PubMed ID: 37487034
    [No Abstract]   [Full Text] [Related]  

  • 18. SGLT2 inhibitors attenuate alterations of kidney metabolic pathways in youth-onset T2DM.
    Carney EF
    Nat Rev Nephrol; 2023 Apr; 19(4):213. PubMed ID: 36849740
    [No Abstract]   [Full Text] [Related]  

  • 19. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does evidence from RCTs suggest: SGLT2 inhibitors could not reduce myocardial infarction and stroke?
    Du L; Li Z; Lan P; Huang H; Cheng W; Xia J
    Eur J Clin Pharmacol; 2022 Oct; 78(10):1703-1704. PubMed ID: 36008491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.